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Abstract
Background: MicroRNA expression is altered in cancer cells, and microRNAs could serve as diagnostic/prognostic biomarker
for cancer patients. Our study was designed to analyze circulating serum microRNAs in patients with renal cell carcinoma
(RCC).
Methodology/Principal Findings: We first explored microRNA expression profiles in tissue and serum using TaqMan Low
Density Arrays in each six malignant and benign samples: Although 109 microRNAs were circulating at higher levels in
cancer patients’ serum, we identified only 36 microRNAs with up-regulation in RCC tissue and serum of RCC patients. Seven
candidate microRNAs were selected for verification based on the finding of up-regulation in serum and tissue of RCC
patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290 levels in serum of healthy controls
(n=30) and RCC (n=33) patients were determined using quantitative real-time PCR (TaqMan MicroRNA Assays). miR-1233
was increased in RCC patients, and thus validated in a multicentre cohort of 84 RCC patients and 93 healthy controls using
quantitative real-time PCR (sensitivity 77.4%, specificity 37.6%, AUC 0.588). We also studied 13 samples of patients with
angiomyolipoma or oncocytoma, whose serum miR-1233 levels were similar to RCC patients. Circulating microRNAs were
not correlated with clinical-pathological parameters.
Conclusions/Significance: MicroRNA levels are distinctly increased in cancer patients, although only a small subset of
circulating microRNAs has a tumor-specific origin. We identify circulating miR-1233 as a potential biomarker for RCC
patients. Larger-scaled studies are warranted to fully explore the role of circulating microRNAs in RCC.
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Introduction
Kidney cancer is one of the most common malignancies in
developed countries [1]. Renal tumors are asymptomatic and non-
palpable inearly stages; morethan 50% of renal tumors are detected
incidentally by imaging to investigate non-specific symptoms. The
most common renal tumor is clear cell renal cell carcinoma
(ccRCC), but other histological subtypes of renal cell carcinoma (i.e.
papillary,pRCC;orchromophobeRCC,chRCC)ornon-malignant
renaltumors (i.e. oncocytoma andangiomyolipoma) aremoreorless
difficult to differentiate by imaging modalities, and additional
diagnostic tools are warranted to optimize the management of
patients with renal tumors. So far, non-invasive biomarkers are not
used in the routine practice because they do not improve the
diagnostic or prognostic accuracy [2].
MicroRNAs are small non-coding RNAs of approximately 22 nt
size,andmodulatedifferentiation,growth,apoptosisandproliferation
of cells. MicroRNA expression profiles not only allow distinguishing
malignant and non-malignant tissue, but also distinguishing different
tumor entities.[3] MicroRNAs are circulating in a cell-free form in
blood [4–6], most probably in exosomes which protect them against
degradation by RNase [4,5]. MicroRNA signatures in blood are
similar in men and women, as well as individuals of different age.[6]
Furthermore, microRNA levels are similar in plasma and serum [4],
and freeze/thaw as well as prolonged storage at room temperaturedo
not affect microRNA levels [4]. Thus, circulating microRNAs have
the potential of a novel biomarker.
Several studies demonstrated that specific microRNAs are
useful to distinguish cancer patients and healthy controls: e.g.,
patients with prostate cancer have increased levels of miR-26a [7],
miR-29 and miR-92a were increased in colon cancer patients [8],
and miR-195 was increased in patients with breast cancer [9]. In
addition, microRNAs were prognostic indicators (prostate cancer:
miR-141 [10]; colon cancer: miR-29 [8]).
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       Methods
Objectives
So far, circulating microRNAs have not been investigated in
patients with renal cell carcinoma. Several groups analyzed
microRNA expression in tissue, with conflicting results. We
therefore designed our study to identify potential candidates using
an array technology (TaqMan Low Density Array), and validate
the most interesting microRNAs in an independent cohort using
conventional real-time PCR. The flow chart of the marker
verification study is shown in Figure 1.
Participants
We collected prospectively serum from patients undergoing
radical nephrectomy or nephron-sparing surgery for renal tumors;
thus, the study cohort consisted of patients with renal cell
carcinoma and benign renal tumors (BRT; i.e. oncocytoma and
angiomyolipoma). We also investigated a control group consisting
of patients with non-malignant disease (men/women attending to
our hospital for surgery of non-malignant disease, i.e. benign
prostate enlargement or urinary incontinence, or preventive
medical examination). The detailed clinical-pathological parame-
ters of patients are reported in Table 1. The collection of serum
samples was performed between 2005 and 2011 at the
Departments of Urology at the Universita ¨tsklinikum Bonn
(UKB), the Universita ¨tsklinikum Mu ¨nster (UKM) and the
Universita ¨tsklinikum des Saarlandes (UKS).
Blood samples were obtained prior surgery. Blood was
withdrawn in serum S-Monovette Gel tubes with clotting activator
(Sarstedt, Nu ¨mbrecht, Germany); after clotting, serum was
separated after centrifugation (10 min, 2800 g) and stored in
cryotubes at 280uC. All samples were processed between 1 and
3 hours. We also analyzed formalin-fixed, paraffin embedded
tissue from six patients stored in the archival files of the Institut fu ¨r
Pathologie at the Universita ¨tsklinikum Bonn.
RNA isolation
Serum RNA isolation was performed as published earlier [7]. In
brief, the mirVana PARIS Kit (Ambion, Foster City, CA, USA)
was used to purify RNA from 400 ml serum. RNA isolation was
performed according to the manufacturers’ recommendation (final
elution volume 50 ml) with one exception: we added 25 fmol of a
synthetic Caenorhabditis elegans microRNA, cel-miR-39 (Qiagen,
Hilden, Germany; catalog number MSY0000010) to the serum
before starting the isolation procedure. Quantification of cel-miR-
39 allows controlling sample-to-sample differences of RNA
isolation efficiency. We analyzed separate (and not pooled)
samples at each step of the study [phase-1: ccRCC n=6, healthy
control n=6; phase-2: ccRCC n=33, healthy control n=30;
phase-3: RCC n=84 (including 69 ccRCC, 10 pRCC, 3 chRCC
and 2 sRCC patients), healthy control n=93, angiomyolipoma
n=3, oncocytoma n=10].
Malignant and non-malignant renal tissue was marked on
haematoxylin and eosin stained slides by a pathologist. Five serial
sections (20 mm) were cut from the tissue block, and the tissue was
dissected using a scalpel to enrich ccRCC and adjacent non-
malignant renal tissue. Afterwards, the RNA was isolated with the
RecoverAll Total Nucleic Acid Isolation Kit (Ambion) according
the manufacturer recommendations. RNA quantity and purity
was determined using the NanoDrop 1000 spectrophotometer
(ThermoScientific, Wilmington, DE; USA).
Low Density Arrays
Reverse transcription was performed using the TaqMan
MicroRNA Reverse Transcription Kit and Megaplex RT Primers.
The reaction mix included 16.6 ng/ml RNA (tissue) or 3 ml of the
eluted RNA (serum). In order to increase the sensitivity of the
TaqMan Low Density Arrays, we performed a pre-amplification
using the TaqMan PreAmp Mastermix. MicroRNA profiling of
754 different human microRNAs was then performed using the
TaqMan Low Density Array (TaqMan Array Human MicroRNA
A+B Cards Set v3.0; see Table S1 for a list of microRNAs) on an
ABIPrism 7900HT. In order to normalize serum microRNA
levels, we additional determined miR-39 levels: RNA was reverse
transcribed with miR-39 RT primers using the TaqMan
MicroRNA Reverse Transcription Kit and quantified using a
real-time PCR (see below for details). All reactions were performed
as specified in the protocols of the manufacturer (Applied
Biosystems, Foster City, CA, USA). Details are reported MIQE-
compliant in Methods S1.
Quantitative Real-Time PCR
We identified seven candidates using the Low Density Array
technology for further characterization. The determination of
microRNA levels in subsequent validation experiments was
performed similar as described above with one exception:
Figure 1. Flow Chart: Verification of miR-1233 as diagnostic marker of renal cell carcinoma.
doi:10.1371/journal.pone.0025787.g001
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pool: To obtain this RT primer pool, we speed vacuumed a
mixture of each 320 ml of cel-miR-39 (Applied Biosystems Assay
ID: 000200), hsa-miR-1233 (ID: 002768), hsa-miR-106b* (ID:
003280), hsa-miR-1290 (ID: 002863), hsa-miR-210 (ID:
4373089), hsa-miR-7-1 (ID: 001388), hsa-miR-320b (ID:
002844) and hsa-miR-93 (ID: 4373302) at 45uC for 3 hours with
the Concentrator 5301 (Eppendorf, Wesseling, Germany). The
RT primer pool was re-suspended in 320 ml nuclease-free water.
For the validation of miR-1233 in a second cohort, the same RT
primer pool was used. Quantitative real-time PCR was
performed using the TaqMan Small RNA Assay on the ABIPrism
7900 HT in triplicates in 10 ml reaction volume; all experiments
were performed as specified in the manufacturers’ protocols. The
detailed experimental procedures are presented MIQE-compliant
in Methods S1.
Ethics
All patients gave written informed consent prior blood
withdrawal. The study was approved by the Ethikkommission an
der Medizinischen Fakulta ¨t der Rheinischen Friedrich-Wilhelms-
Universita ¨t Bonn (approval number: 166/10).
Statistical methods
The analysis of the real-time PCR data was done using with the
SDS software v2.4 (settings: automatic baseline, threshold 0.2);
relative microRNA levels were calculated with the RQ Manager
v1.2.1, and data was analyzed with DataAssist v2.0 (all software
packages: Applied Biosystems). MicroRNA levels in serum were
normalized against miR-39 because circulating levels of potential
microRNA reference genes are also increased in serum of cancer
patients [7] and normalization to a spiked-in synthetic microRNA
allows to control for RNA isolation efficiency; tissue microRNA
expression was normalized against RNU6, RNU44 and RNU48.
Statistical analyses were performed using PASW statistics 17.0
(SPSS, Chicago, IL, USA): Sensitivity, specificity and area under
curve (AUC) for microRNA levels were determined using Receiver
Operator Characteristic (ROC) analysis. Clinical-pathological
parameters and microRNA levels were correlated using the
Mann-Whitney-U or Kruskal-Wallis-test, as appropriate.
Results
Phase-1: Marker-Discovery
First, we determined microRNA expression in ccRCC and
adjacent non-malignant tissue (both n=6) of 754 microRNAs
using TaqMan Low Density Arrays. MicroRNA expression was
normalized to small nuclear RNA (RNU6B, RNU44, RNU48),
and the mean expression level was calculated. Eighty-three
microRNAs were .2-fold upregulated, and 103 microRNAs were
downregulated (,2-fold); similar expression levels were seen in
277 microRNAs and 299 microRNAs were not detectable. See
Table S1 for Ct-values.
Next, we determined the microRNA profile in serum from these
patients, and compared the expression profile to healthy
individuals (each n=6); in order to control the isolation efficiency,
the microRNA expression was normalized to miR-39, which was
spiked to serum prior the RNA isolation procedure. In RCC
patients, 189 microRNAs were upregulated, 9 downregulated and
120 expressed at similar levels; 444 microRNAs were not detected
in serum. Raw data is provided in the Table S1.
We then compared microRNA profiles of serum and tissue to
discover potential tumor-specific microRNAs which could serve as
non-invasive diagnostic biomarker: 36 microRNAs were circulat-
ing at increased levels in cancer patients and overexpressed in
corresponding ccRCC tissue (see Figure 2 and Table 2). The
criteria for further investigation of the seven most promising
candidates were: (i) high microRNA level in serum of cancer
patients, (ii) high microRNA level in RCC tissue, and (iii)
quantification cycle values ,30 to enable reliable detection. Based
on these criteria, we selected miR-106b*, miR-1233, miR-1290,
miR-210, miR-7-1*, miR-320b and miR-93.
Phase-2: Marker-Verification
The levels of seven promising microRNAs were determined
using quantitative real-time PCR in a cohort of 33 patients with
ccRCC and 30 urological patients with non-malignant disease;
microRNA levels were normalized to miR-39. The level of miR-
1233 was significantly increased in patients with RCC (mean 2.19;
95%CI 1.57-2.81) compared to healthy controls (mean 1.49;
95%CI 1.11-1.86; p=0.022). Using ROC analysis we determined
a sensitivity of 90.9% and a specificity of 50% (threshold 0.93;
AUC=0.669, 95%CI=0.531-0.807). The circulating levels of
miR-106b* (p=0.137), miR-1290 (p=0.262), miR-210 (p=
0.342), miR-320b (p=0.308), miR-7-1* (p=0.199) and miR-93
(p=0.483) were not different in RCC patients and healthy
individuals. See Figure 2.
Table 1. Clinical-pathological parameters.
PHASE I PHASE II PHASE III
RCC HI RCC HI RCC HI BRT
Sex
male 3 3 27 21 56 68 6
f e m a l e 33692 8 2 5 7
Age
mean 66.0 47.7 62.7 60.2 60.9 63.7 59.5
median 66.0 47.5 65.0 63.0 63.0 64.0 63.0
range 57–75 40–60 43–80 26–85 25–82 28–88 21–84
Histology
ccRCC 6 n.a. 33 n.a. 69 n.a. n.a.
pRCC 0 n.a. 0 n.a. 10 n.a. n.a.
chRCC 0 n.a. 0 n.a. 3 n.a. n.a.
sRCC 0 n.a. 0 n.a. 2 n.a. n.a.
Pathological stage
pT1 2 n.a. 23 n.a. 55 n.a. n.a.
pT2 1 n.a. 3 n.a. 4 n.a. n.a.
pT3 3 n.a. 7 n.a. 23 n.a. n.a.
pT4 0 n.a. 0 n.a. 2 n.a. n.a.
vascular invasion 3 n.a. 3 n.a. 12 n.a. n.a.
lymph node
metastasis
0 n.a. 0 n.a. 8 n.a. n.a.
distant metastasis 0 n.a. 0 n.a. 5 n.a. n.a.
Fuhrman Grade
G1 0 n.a. 4 n.a. 11 n.a. n.a.
G2 6 n.a. 28 n.a. 62 n.a. n.a.
G3 0 n.a. 1 n.a. 8 n.a. n.a.
G4 0 n.a. 0 n.a. 3 n.a. n.a.
Abbreviations: RCC, renal cell carcinoma; HI, healthy individuals; BRT, benigne
renal tumor; ccRCC, clear cell RCC; pRCC, papillary RCC; chRCC, chromophobe
RCC; sRCC, sarcomatoid RCC; n.a., not applicable.
doi:10.1371/journal.pone.0025787.t001
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We thus investigated miR-1233 levels using the same method in
an independent cohort of 84 patients with RCC (ccRCC n=69;
pRCC n=10; chRCC n=3; sRCC n=2) and 93 healthy controls;
we also analyzed 3 patients with angiomyolipoma and 10 patients
with oncocytoma. We could confirm that miR-1233 levels are
increased in patients with RCC (p=0.044): the mean (95%
confidence interval) level of miR-1233 was 2.05 (1.58–2.53) in
RCC patients and 1.88 (1.61–2.17) in healthy controls. Using
ROC analysis we determined a sensitivity of 77.4% and a
specificity of 37.6% at a threshold of 1.15 (AUC 0.588, 95%
confidence interval 0.505–0.671; accuracy 55.9%; precision
52.4%; false positive rate 63.4%; see Figure 2); sensitivity
(84.5%) and specificity (28.5%) were somewhat lower if the
threshold of 0.93 was applied, which was determined in the
smaller cohort from Phase-1. The diagnostic information was
similar if only patients with ccRCC and healthy controls were
compared (AUC 0.590, 95% confidence interval 0.503–0.678;
accuracy 53.1%; precision 46.8%; false positive rate 63.4%). It
should also be noted that miR-1233 levels from RCC patients and
healthy controls at the UKM were somewhat increased compared
to patients from UKB or UKS (see Figure 2). However, the
number of samples from the centers differed (UKB: 85 healthy, 4
BRT, 56 RCC; UKM: 8 healthy, 1 BRT, 14 RCC; UKS: 8 BRT,
14 RCC), and make more detailed interpretation difficult.
Due to the low number of patients with pRCC, chRCC or
sRCC, we did not compare miR-1233 levels within different
histological subtypes. Clinical-pathological parameters were not
correlated with miR-1233 levels in RCC patients (sex: p=0.300;
pT-stage: p=0.735; lymph node metastasis: p=0.715; Fuhrman
grade: p=0.215). Of interest, patients with benign renal tumors
(angiomyolipoma, oncocytoma) had similar miR-1233 levels as
cancer patients (see Figure 2).
In an earlier study [7], we reported lower microRNA isolation
efficiencies in patients with prostate cancer; in the present study,
patients with RCC had a similar recovery of miR-39: mean (95%
CI) recovery was 37.8% (34.2%–41.4%) in RCC patients and
36.1% (32.5%–39.7%) in healthy controls. However, microRNA
isolation was quite variable with a standard deviation of 16.7%.
We did not notice a difference of microRNA recovery between the
study centers.
Discussion
Pioneering studies on circulating serum/plasma microRNAs
[4–6] showed that circulating microRNAs are potential tumor
markers: microRNAs are stable in blood and their signatures are
independent of age and sex. Consequently, researchers demon-
strated increased microRNA levels in serum/plasma of patients
with various tumor entities [7–9;11–15]. Former studies demon-
Figure 2. Serum microRNA levels in patients with renal cell carcinoma, benign renal tumors and healthy controls. MicroRNAs were
profiled in serum and tissue of patients with clear cell renal cell carcinoma (ccRCC) and healthy controls (each n=6) using the TaqMan Low Density
Array; 36 microRNAs were upregulated in RCC tissue and serum of RCC patients (Phase-1). Seven microRNAs were chosen for verification using real-
time PCR in a cohort of 33 ccRCC and 30 healthy individuals (Phase-2). In Phase-3, the finding of increased serum miR-1233 levels in RCC patients was
confirmed in a multicentre cohort of 84 RCC, 93 healthy and 13 benign renal tumors (BRT). MicroRNA recovery (as determined using quantification of
the synthetic miR-39) was similar in the study centers (UKB, UKM, UKS); the level of miR-1233 were somewhat higher in patients from UKM.
doi:10.1371/journal.pone.0025787.g002
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renal tissue is different [16–24], although findings regarding the
number and type of up-/down-regulated microRNAs are
conflicting. Thus, circulating microRNAs may also be a suitable
biomarker for patients with RCC. To the best of our knowledge,
this is the first study on circulating microRNAs in patients with
RCC.
So far, there is no consensus on a set of upregulated microRNAs
in RCC which could be used as non-invasive biomarker. We
therefore compared the microRNA expression profile of normal
and cancerous serum/tissue; this approach allowed the identifica-
tion of 36 microRNAs with relative tumor-specificity upregulated
in serum of RCC. Most of these microRNAs were already
recognized as overexpressed in RCC tissue in previous studies (e.g.
miR-15a, miR-16, miR-21, miR-34b, miR-106b, miR-155, miR-
210, miR-142-5p [16–25]), whereas miR-1290 and miR-30d were
downregulated [25]. The accordance of upregulated microRNAs
in our study with earlier reports indicates the validity of our
findings in Phase-1, even though the discovery cohort in our study
was restricted to each six RCC and control tissue/serum samples.
It is of great interest that our study is the first to identify miR-1233
as RCC-associated oncomir. Similar to earlier studies, we
observed that microRNAs were predominantly downregulated
(103 vs. 83) in RCC tissue. In comparison, an overwhelming
number of microRNAs were increased in serum of RCC patients
(189 vs. 9). This indicates that circulating microRNAs are
generally increased in RCC patients, and that, besides a limited
amount of more tumor-specific microRNAs, many of these
upregulated serum microRNAs originate from healthy cells. We
earlier noted similar findings for cell-free serum DNA, which is
mainly composed of DNA from normal cells [26–29], and
hypothesized that pro-apoptotic signals from cancer-cells lead to
cell death of adjacent normal cells. However, additional reasons
for this difference are possible: (i) In order to identify cancer-
associated microRNAs in serum, we compared microRNA
expression profiles of serum, cancerous and non-malignant tissue
of the same cancer patient, whereas serum from different
individuals was used. (ii) The different normalization strategy in
serum (cel-miR-39) and tissue (RNU6, RNU44, RNU48) may also
contribute to different numbers of upregulated microRNAs in
tissue and serum.
We next validated the diagnostic potential of seven candidates
from the array experiments in cohort of ccRCC patients.
Surprisingly, only miR-1233 was circulating at increased concen-
trations in patients with RCC, whereas differences were no longer
observed for miR-106b*, miR-1290, miR-210, miR-320b, miR-7-
1* and miR-93. Importantly, we were able to confirm the increase
of miR-1233 in serum of RCC patients compared to healthy
controls in a multicentre-cohort. Although the diagnostic infor-
mation (sensitivity 77%, specificity 37.6%, AUC 0.588) was below
the expectations after the initial experiments, it should be kept in
mind that ‘‘accepted’’ diagnostic biomarkers like PSA do not have
a better diagnostic performance for prostate cancer. A relatively
small number (n=13) of oncocytoma and angiomyolipoma did
not show different miR-1233 levels, and thus the value of miR-
1233 for the differential diagnosis of solid renal tumors needs to be
clarified in larger-scaled, future studies. A recent study published
by Youssef et al. [24] demonstrated that microRNA expression
profiles allow to distinguish between RCC and oncocytoma, thus
maybe more than a single microRNA needs to be investigated to
improve the diagnostic information.
Our study is the first on miR-1233, and information about the
function of this microRNA located on chromosome 15q14 is
missing. The microRNA target prediction software miRWalk [30]
identified several potential microRNA binding sites: Most of them
are genes with unknown function, but there are also tumor-
associated genes like BLCAP (identified as tumor suppressor gene
in bladder cancer [31]) or p53 among the potential targets.
A strength of our study is the use of samples from three different
study centers for validation; other studies on circulating micro-
RNAs in cancer patients only analyzed samples from one centre.
Interestingly, we observed higher levels of miR-1233 in healthy
individuals and cancer patients in one centre (UKM). This finding
must be interpreted with caution because of the different number
of patients recruited in each centre, but indicates clearly the
necessity of multicentre evaluation of novel biomarkers.
Table 2. MicroRNAs with .2-fold overexpression in serum
and tissue of renal cell carcinoma patients.
microRNA Assay-ID
expression
tissue
expression
serum
miR-106b 002380 2.708 11.784
miR-1233 002768 2.021 10.600
miR-1290 002863 2.811 6.984
miR-30d* 002305 6.209 5.746
miR-210 4373089 20.718 5.685
miR-425* 002302 3.963 5.091
miR-7-1 001338 2.487 5.051
miR-190b 002263 2.066 4.769
miR-30b 002984 2.103 4.526
miR-93 4373302 2.488 4.429
miR-374a 002125 4.304 4.385
miR-223 002098 2.486 3.972
miR-15a 4373123 3.438 3.927
miR-223 4395406 3.008 3.774
miR-942 002187 2.450 3.591
miR-590-5p 4395176 2.239 3.542
miR-642 4380995 4.241 3.260
miR-193 4395392 2.417 3.257
miR-635* 002432 2.193 3.023
miR-19a 4373099 2.004 2.864
miR-155 4395459 12.898 2.860
miR-16 4373121 2.128 2.813
miR-629* 001562 2.814 2.796
miR-34b 002102 2.556 2.720
miR-301b 4395503 2.765 2.534
miR-1271 002779 3.305 2.504
miR-130b 4373144 2.060 2.478
miR-195 4373105 2.885 2.413
miR-181a 00516 2.563 2.386
miR-21 4373090 4.552 2.355
miR-142-5p 4395359 8.588 2.239
miR-629 4395547 2.972 2.186
miR-25 4373071 2.346 2.176
miR-16-1* 002420 2.360 2.061
miR-15b 4373122 3.318 2.034
miR-23a 4373074 2.128 2.017
doi:10.1371/journal.pone.0025787.t002
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against cel-miR-39 (as earlier described by Mitchell et al. [4]),
which allows absolute quantification of circulating microRNAs
with normalization to technical variability. Often, larger RNA
species (i.e. U6 or RNU6b) are prone to degradation by serum
RNases, and thus normalization to these classical reference genes
for microRNA studies is not reasonable. An effective normaliza-
tion strategy for biological variation is not well-developed and
factors leading to biological variation independent of RCC are not
known, and their effect on specific microRNAs has not been
characterized [32]. Thus, absolute quantification is an appropriate
approach for the analysis of circulating microRNAs.
Limitations
Some limitations should be named: The number of samples in
Phase-1 was limited to six, and more samples would have probably
allowed us to identify a better microRNA panel for verification/
validation. Also, samples from six healthy individuals who were
younger than the RCC patients served as controls, and these
samples could be a potential bias. In addition, the cancer cohort in
phase-1 consisted only of patients with ccRCC, and is therefore
less suitable to identify a marker for patients with non-ccRCC
histology. Larger-scaled future studies are warranted to explore the
role of circulating microRNAs in RCC patients; it is of outstanding
importance to analyze serum of patients with non-ccRCC and
non-malignant renal tumors for a better understanding of
microRNAs is biomarkers for RCC. However, we were able to
identify miR-1233 as cancer-associated, cell-free circulating
microRNA with potential use in the diagnosis of RCC in the
multicenter validation cohort. We did not observe a correlation of
miR-1233 and clinical-pathological parameters; it should be kept
in mind, that recruiting was performed for a diagnostic study, and
thus the composition of the study cohort is unlikely to reveal
prognostic information (most patients have moderately differenti-
ated (74% G2) and organ-confined (70%) tumors). Novel
biomarkers for RCC should also provide information during
follow-up to aid the diagnosis of recurrence; blood samples for this
purpose were not available, and thus this question has to be
answered by future studies.
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